Navigation Links
Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured''

WASHINGTON--(BUSINESS WIRE)--May 21, 2007 - Results from a new study, presented at the 38th annual Digestive Disease Week (DDW) conference, showed that more than 99 percent of patients with chronic hepatitis C virus (HCV) infection who were treated successfully with PEGASYS(R) (peginterferon alfa-2a) had no detectable virus up to seven years later - validating the use of the word "cured" to describe these patients, according to study authors. Currently, the best indicator of treatment success is a sustained viral response (SVR), defined as undetectable hepatitis C virus in the blood six months after the end of treatment. The results announced today are from a long-term follow-up study to determine whether the virus re-emerges in patients who achieve an SVR. (Studies show that, overall, about half of patients with hepatitis C monoinfection can achieve an SVR with PEGASYS and ribavirin treatment, the current standard of care.)

"The results announced today are encouraging because it is rare in the treatment of life-threatening viral diseases that can we tell patients they have the chance for a cure," said Dr. Mitchell L. Shiffman, Professor of Medicine, Chief of Hepatology and Medical Director of the Liver Transplant Program, Virginia Commonwealth University Medical Center, and study author. "But in hepatitis C today, we are able to help some patients achieve an outcome that effectively enables them to put their disease behind them."

About the Study (Abstract ID #444)

This study monitored 997 patients (either mono-infected with chronic HCV or co-infected HCV and HIV) who achieved an SVR following treatment with PEGASYS monotherapy or combination therapy with PEGASYS and ribavirin. Serum levels of HCV were monitored on an annual basis for an average of 4.1 years (range 0.4 to 7 years) following successful treatment. Of the 997 patients, 989 (greater than 99 percent) maintained undetectable levels of H
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Inc. (NASDAQ:INSM), a ,biopharmaceutical company focused on the development ... diseases with unmet,medical needs, today announced that it ... Growth,Opportunities Conference in New York City. ... Oriental Hotel in New,York City, will run from ...
... 9, 2007 - Neose Technologies,Inc. (NasdaqGM:NTEC) announced today ... Emerging Growth Opportunities Conference,held at the Mandarin Oriental ... The Company's presentation is scheduled for 2:00 p.m.,(EDT) ... be webcast,live and available for replay via the ...
Cached Medicine Technology:Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... are personal and subjective, the human brain turns ... emotions across different senses, situations and even people, ... Adam Anderson. , "We discovered that fine-grained patterns ... area of the brain associated with emotional processing, ... individual,s subjective feeling," says Anderson, associate professor of ...
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... smell of flatulence and have a reputation for being highly ... sulfide is now being being found to offer potential health ... heart attacks and dementia. A new compound (AP39), designed and ... to future therapies, by targeting delivery of very small amounts ... cells. , Scientists in Exeter have already found that ...
(Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... , , , WASHINGTON, ... Produce Safety Project: , , We commend the FDA ... The proposed guidance documents put out for comment today address three ... these documents quickly. We also look forward to the agency,s next ...
... ... in Webinar Series on "How Generation and Gender Impact Physician Engagement" , ... Charlotte, N.C. (Vocus) July 31, 2009 -- ... in Physician Engagement." The free hour-long ,webinar will be broadcast on Wednesday, August ...
... SHENZHEN, China, July 31 /PRNewswire-FirstCall/ ... announced today that its,registration dossier for MEVAC-DTaP (Diphtheria, Tetanus ... consideration,of the experts in Thai FDA. The sample analysis ... , Mr. Terry Yuan CEO ...
... , COLUMBIA, S.C., July 31 Amid rising ... benefits of including international medical travel coverage in their employee ... possible risks associated with offering such options. , , ... Global Healthcare Inc. today announced an agreement with an insurer ...
... skills, researchers say , FRIDAY, July 31 (HealthDay News) ... should learn cardiopulmonary resuscitation (CPR), Austrian researchers say. , In ... life-support training, 86 percent of the children performed CPR correctly ... to the report published online in the journal Critical ...
... , , , ... Language Line Services , the leading provider of ... evening, July 23rd at a Recognition and Awards Banquet at Bellevue University, ... Wray, President of the Nebraska Association for Translators & Interpreters (NATI), said, ...
Cached Medicine News:Health News:Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates 2Health News:Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates 3Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 2Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 3Health News:New Policies Protect Employers, Workers Who Choose Global Health Care 2Health News:Even 9-Year-Olds Can Learn CPR 2Health News:Language Line Services Honored by Nebraska Association for Translators & Interpreters (NATI) 2Health News:Language Line Services Honored by Nebraska Association for Translators & Interpreters (NATI) 3
When You Need Optimal Patient Comfort with Minimal Weight at a Nonunion Site...Demand The OrthoPak Noninvasive Bone Growth Stimulator., ,Most Appropriate for the Proximal Femur, Metatarsal/Tarsal...
... Providing the surgical versatility you demand when ... new EBI OsteoGen-D offers 40 microamperes of ... each with 20 microamperes. Available in both ... superior flexibility with any of your bone ...
... cataract surgery following refractive surgery grows larger ... for surgeons, as calculating IOL power for ... power following RK, ALK, PRK and LASIK ... or topography. For example, keratometry and simulated ...
... to offer one of the ... at only 188 grams! The ... superior flow rate with effortless ... The complementing electrodes provide powerful ...
Medicine Products: